Larimar Therapeutics, Inc. (LRMR)

NASDAQ • Healthcare

$2.35

+$0.08 (+3.5%)

Market closed

Last close at October 23, 2026 at 20:00 UTC

Open$2.27

Day Range$2.22 - $2.37

Avg. Volume (3M)1.5M

Market Cap$244.1M

52 Week Range

$1.92$6.42

Metrics Over Time

Fundamentals & Financials

Revenue (TTM)

Net Income (TTM)

-$172.6M

EPS (TTM)

-$1.99

ROA (TTM)

-104.42%

Current Ratio

4.7

TTM is calculated as the sum of the four most recently completed quarters. This is a standard approach when monthly or real-time data is not available.

Income Statement

Balance Sheet

Financial Highlights

Dividends History

Split History

Earnings

+12.8%Q3 2025-$0.41

-56.4%Q4 2025-$0.61

-65.9%Q1 2026-$0.73

+41.5%Q2 2026-$0.31

+21.4%Q3 2026-$0.3

% — EPS deviation from the forecast (beat / miss); quarters without a forecast show the reported EPS

Latest report — Q3 2026

Beat +21.4%

Larimar Therapeutics’ loss narrowed versus expectations, with EPS of -$0.30 topping the -$0.38 estimate by $0.08, based on preliminary results for the second fiscal quarter of 2026 that were reported August 4, 2026. As a clinical-stage biotech focused on its CTI-1601 program for Friedreich’s ataxia, the quarter remained characterized by operating spending rather than product revenue, with operating income at about -$34.4 million and net income at roughly -$32.8 million. Net income declined 25.2% year over year from roughly -$26.2 million a year ago, and cash usage was reflected in negative operating cash flow of about -$44.0 million. For the next period, consensus calls for EPS of -$0.35.

Next report — what to expect

Larimar Therapeutics, Inc. (LRMR) is set to report earnings on November 5, 2026. Consensus calls for EPS of -$0.37. The company has beaten EPS in 4 of 8 most recent quarters, so attention will be on whether results and commentary align with that cadence around the release.

View full earnings history

About Larimar Therapeutics, Inc.

Larimar Therapeutics, Inc. is a NASDAQ-listed healthcare company in biotechnology that operates as a clinical-stage drug developer focused on rare diseases. The company centers its work on CTI-1601, a therapy candidate for Friedreich's ataxia, and its current profile is that of an early-stage biotech rather than a commercial medicine business.

Name

Larimar Therapeutics, Inc.

CEO

Carole S. Ben-Maimon

Website

www.larimartx.com

Industry

Healthcare

Employees

Today's Snapshot

AI-generated

LRMR closed 3.5% higher at 2.35, outperforming a weaker sector. Shares changed hands at about half of its usual level.

Trading Volume

Below 10d avg (2.1M)

1.1M

vs S&P 500 Today

Strong Outperformance

+4.04%

Updated: October 23, 2026 at 20:25 UTC

Technical Indicators

0 Buy3 Neutral5 Sell

LRMR exhibits pronounced weakness with the current price near 2.35 while most short-, medium- and long-term averages lie above the market, signaling pervasive selling pressure. ADX is robust around 42, indicating a strong downtrend, and momentum indicators are negative while ATR of about 8.8% reflects elevated volatility. On-balance volume strongly favors sellers, reinforcing distribution, and the pivot sits essentially at the market offering little support. Technical takeaway: Strong Sell.

All signals

EMA (5 indicators)$2.36 - $3.67
Sell
RSI (14)36.19
Neutral
Stochastic %K (14, 3, 3)39.05
Neutral
MACD Level (12, 26)-0.34
Neutral

Peers & Related Assets

LXEOLexeo Therapeutics, Inc. Common Stock

$2.8-3.1%

KRROKorro Bio, Inc.

$11.98-0.6%

ANROAlto Neuroscience, Inc.

KYTXKyverna Therapeutics, Inc.

Stay Ahead of the Market

Get premium market insights delivered directly to your inbox.